JP2007527409A - β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法 - Google Patents

β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法 Download PDF

Info

Publication number
JP2007527409A
JP2007527409A JP2006534354A JP2006534354A JP2007527409A JP 2007527409 A JP2007527409 A JP 2007527409A JP 2006534354 A JP2006534354 A JP 2006534354A JP 2006534354 A JP2006534354 A JP 2006534354A JP 2007527409 A JP2007527409 A JP 2007527409A
Authority
JP
Japan
Prior art keywords
inverse agonist
pulmonary
adrenergic
adrenergic inverse
airway disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527409A5 (enExample
Inventor
ボンド、リチャード、エイ．
Original Assignee
インバーセオン、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インバーセオン、インコーポレイテッド filed Critical インバーセオン、インコーポレイテッド
Publication of JP2007527409A publication Critical patent/JP2007527409A/ja
Publication of JP2007527409A5 publication Critical patent/JP2007527409A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
JP2006534354A 2003-10-09 2004-10-08 β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法 Pending JP2007527409A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51025003P 2003-10-09 2003-10-09
US55579704P 2004-03-23 2004-03-23
PCT/US2004/033157 WO2005034871A2 (en) 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists

Publications (2)

Publication Number Publication Date
JP2007527409A true JP2007527409A (ja) 2007-09-27
JP2007527409A5 JP2007527409A5 (enExample) 2008-01-17

Family

ID=34437322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534354A Pending JP2007527409A (ja) 2003-10-09 2004-10-08 β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法

Country Status (7)

Country Link
US (1) US9539221B2 (enExample)
EP (2) EP1684764A2 (enExample)
JP (1) JP2007527409A (enExample)
AU (2) AU2004280638A1 (enExample)
CA (2) CA2544611A1 (enExample)
IL (1) IL174765A0 (enExample)
WO (2) WO2005035731A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502635A (ja) * 2011-01-10 2014-02-03 インヴァージアン， インコーポレイテッド 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
WO2005089741A2 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
JP2007536350A (ja) * 2004-05-10 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺気腫の予防又は治療のためのロフルミラストの使用
US8691877B2 (en) 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
US20090214643A1 (en) * 2005-07-19 2009-08-27 Franklin Amie E Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
AU2010282202B2 (en) * 2009-08-12 2014-10-09 Isonea Australia Pty Ltd Determining dynamic airway response in a subject
US11382513B2 (en) 2016-11-08 2022-07-12 Palo Alto Investors Methods and compositions for treating a condition in a subject
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US10947196B2 (en) 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
US11607395B2 (en) 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
CA3211268A1 (en) * 2021-03-09 2022-09-15 Chronic Airway Therapeutics Limited Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
US12616667B2 (en) 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
US20260232607A1 (en) * 2022-06-21 2026-08-13 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
WO2023250332A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
CN116199596B (zh) * 2023-03-06 2025-03-25 梯尔希（南京）药物研发有限公司 一种特布他林代谢物的制备方法
AU2024234602A1 (en) * 2023-03-13 2025-10-30 Chronic Airway Therapeutics Limited USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36547A (en) * 1862-09-23 Improvement in locks
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5633259A (en) * 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6673558B1 (en) * 1992-09-30 2004-01-06 Richard G. Lanzara Drug compositions to prevent desensitization of cellular receptors
US6593094B2 (en) * 1992-09-30 2003-07-15 Richard G. Lanzara Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs
US5597699A (en) * 1992-09-30 1997-01-28 Lanzara; Richard G. Method for determining drug compositions to prevent desensitization of cellular receptors
US5585348A (en) * 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
JPH10251147A (ja) 1997-03-06 1998-09-22 Akira Matsumori 炎症性疾患の予防・治療剤
US6284800B1 (en) * 1997-03-13 2001-09-04 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of asthma
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420541B1 (en) * 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
NZ505651A (en) * 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
US6218402B1 (en) * 1998-06-10 2001-04-17 Arena Pharmaceuticals, Inc. Acetylcholine enhancers
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420563B1 (en) * 1998-07-31 2002-07-16 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
CA2402392A1 (en) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
AU2001292897A1 (en) 2000-09-21 2002-04-02 Richard Agustin Bond Novel therapy
YU33103A (sh) * 2000-10-31 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Formulacija rastvora za inhalaciju sa soli tiotropijuma
US7018812B2 (en) * 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
JP2005500258A (ja) * 2001-03-23 2005-01-06 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Ｇｍ１ガングリオシドを阻害することによる、鎮痛効力を増大し、そして、ニ峰作用性オピオイドアゴニストの有害な興奮性効果を減弱する方法。
AU2002309196A1 (en) * 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding olfactory receptors
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502635A (ja) * 2011-01-10 2014-02-03 インヴァージアン， インコーポレイテッド 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用
US9993444B2 (en) 2011-01-10 2018-06-12 Invion, Inc. Use of beta-adrenergic inverse agonists for smoking cessation

Also Published As

Publication number Publication date
WO2005035731A2 (en) 2005-04-21
AU2004280638A1 (en) 2005-04-21
EP1684764A2 (en) 2006-08-02
CA2544611A1 (en) 2005-04-21
WO2005035731A3 (en) 2006-01-12
AU2004279438A2 (en) 2005-04-21
US20080254022A1 (en) 2008-10-16
AU2004279438A1 (en) 2005-04-21
CA2544733A1 (en) 2005-04-21
IL174765A0 (en) 2008-04-13
US9539221B2 (en) 2017-01-10
AU2004280638A2 (en) 2005-04-21
EP1677778A2 (en) 2006-07-12
WO2005034871A3 (en) 2005-11-24
WO2005034871A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
US9539221B2 (en) Method of treating airway diseases with β-adrenergic inverse agonists
JP6827948B2 (ja) 呼吸器疾患の治療
US20100286224A1 (en) Method of treating airway diseases with beta-adrenergic inverse agonists
US20110053986A1 (en) Respiratory disease treatment
US20240180854A1 (en) Use of beta-adrenergic inverse agonists for smoking cessation
US20150238456A1 (en) Methods and compositions for administration of oxybutynin
US20070276024A1 (en) Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
WO2008002929A2 (en) Heterologous cross-sensitization for improved agonist activity
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
CN117999073A (zh) 纳多洛尔通过阻断抑制蛋白-2途径来治疗慢性阻塞性肺病的用途
HK1197916A (en) Use of beta-adrenergic inverse agonists for smoking cessation
HK1197916B (en) Use of beta-adrenergic inverse agonists for smoking cessation
JP2005539058A (ja) 選択的なホスホジエステラーゼ４−阻害物質による非アレルギー性鼻炎の治療
CN101505758A (zh) 含有噻唑衍生物作为活性成分的药物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111111